GSK, Pfizer and J&J expected to go head-to-head in $10 billion RSV market

Fierce competition expected in coming years with leading pharma companies going head-to-head with vaccine candidates.



According to a report from SVB Leerink, the three pharma heavyweights are expected to battle it out for a leading role in the Respiratory Syncytial Virus (RSV) space in the coming years. This past week, Pfizer kicked off a Phase III RSV vaccine trial looking to enrol as many as 30,000 participants. The trial’s pivotal readout is expected to come as early as the first quarter of 2022. J&J launched its own pivotal adult RSV vaccine trial this past month and is likely to have its results announcement align closely with Pfizer’s. GSK, on the other hand, expects its pivotal trial results readout to come during the second half of 2022 – pitting the three closely together in what is likely to be a noteworthy race for a piece of the market is forecasted to reach $10 billion by 2030.


Another emerging player, in the form of Bavarian Nordic is also not too far behind in the race. This past week, the Danish biotech released promising results from a Phase II challenge trial. The hotly contested market is also expected to feature other heavyweights such as Moderna, Sanofi and AstraZeneca. Moderna, which has had its mRNA-based COVID-19 form part of the arsenal against the current pandemic, scored an FDA fast-track designation to leverage its mRNA platform to develop an RSV vaccine just last month. It has since started a Phase 1 trial for its vaccine involving children, younger adults and older adults. Sanofi and AstraZeneca are also reportedly collaborating on a potential blockbuster monoclonal antibody aimed at protecting infants against the virus.